![conference banner](/images/conference-banner.jpeg)
Abstract
In the present study, Poly (D,L-lactide-co-glycolide) microspheres (PLGA MSs) were prepared for delivering a novel oligopeptide derived from rhBMP-2 (Peptide-24). Hydroxypropyl-β-cyclodextrin (HP-β-CD) and Bovine serum albumin (BSA) were used as stabilizers for retaining bioactivity of the oligopeptide. The morphology, diameter, drugloading rates and encapsulation rates of the PLGA MSs were detected and compared. The PLGA MSs were incubated for 3 and 30 days respectively to obtain the release supernatant containing Peptide-24. The structure and bioactivity of released Peptide-24 from PLGA MSs were evaluated through physicochemical detections and cell culture. The structure integrity of the Peptide-24 was confirmed by Far-UV circular dichroism and matrix-assisted laser desorption/ionization time-of-flight Mass Spectrometer (MALDI-TOF-MS) analysis. The interaction between PLGA matrix and loaded Peptide- 24 was verified through Raman. The results showed that the diameter of PLGA MSs was from 8.62 to 15.34 μm, the loading rate was 0.7-0.8%, and the encapsulation rate was 69.3-85.3%. The released Peptide-24 from PLGA MSs was proved to retain original bioactivity by the cellular activity and alkaline phosphatase (ALP) test. HP-β-CD is a kind of excellent stabilizer for retaining the bioactivity of Peptide-24 in PLGA MSs.
Keywords: Poly (D, L-lactide-co-glycolide), microencapsulation, peptides, stabilization, cell culture, bioactivity.
Medicinal Chemistry
Title:Effect of Stabilizers on Bioactivity of Peptide-24 in PLGA Microspheres
Volume: 9 Issue: 8
Author(s): Mingbo Wang, XiaoDong Guo, Rongwei Tan, Zhending She and Qingling Feng
Affiliation:
Keywords: Poly (D, L-lactide-co-glycolide), microencapsulation, peptides, stabilization, cell culture, bioactivity.
Abstract: In the present study, Poly (D,L-lactide-co-glycolide) microspheres (PLGA MSs) were prepared for delivering a novel oligopeptide derived from rhBMP-2 (Peptide-24). Hydroxypropyl-β-cyclodextrin (HP-β-CD) and Bovine serum albumin (BSA) were used as stabilizers for retaining bioactivity of the oligopeptide. The morphology, diameter, drugloading rates and encapsulation rates of the PLGA MSs were detected and compared. The PLGA MSs were incubated for 3 and 30 days respectively to obtain the release supernatant containing Peptide-24. The structure and bioactivity of released Peptide-24 from PLGA MSs were evaluated through physicochemical detections and cell culture. The structure integrity of the Peptide-24 was confirmed by Far-UV circular dichroism and matrix-assisted laser desorption/ionization time-of-flight Mass Spectrometer (MALDI-TOF-MS) analysis. The interaction between PLGA matrix and loaded Peptide- 24 was verified through Raman. The results showed that the diameter of PLGA MSs was from 8.62 to 15.34 μm, the loading rate was 0.7-0.8%, and the encapsulation rate was 69.3-85.3%. The released Peptide-24 from PLGA MSs was proved to retain original bioactivity by the cellular activity and alkaline phosphatase (ALP) test. HP-β-CD is a kind of excellent stabilizer for retaining the bioactivity of Peptide-24 in PLGA MSs.
Export Options
About this article
Cite this article as:
Wang Mingbo, Guo XiaoDong, Tan Rongwei, She Zhending and Feng Qingling, Effect of Stabilizers on Bioactivity of Peptide-24 in PLGA Microspheres, Medicinal Chemistry 2013; 9 (8) . https://dx.doi.org/10.2174/1573406411309080014
DOI https://dx.doi.org/10.2174/1573406411309080014 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Structural Proteomics: Detection of Neurodegenerative Protein Modifications
Current Protein & Peptide Science The Current Use of Mass Spectrometry in Combination with Other Separation Techniques in Drug Discovery Arena
Medicinal Chemistry The Association of Potassium Status with Parameters of Glucose Metabolism is influenced by Age in Adults
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Signaling Mechanisms of Gustatory Perception of Lipids: Can the Taste Cells be the Target of Anti-obesity Agents?
Current Medicinal Chemistry The Prognostic Impact of Pleural Invasion in Lung Cancer According to the UICC Classification
Current Respiratory Medicine Reviews Human Platelet-Derived Growth Factor Enhances Healing of Ulcers Situated on Non-Foot Sites in Diabetics. A Pilot Study
Current Drug Therapy Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Epidemiological Characteristics and Risk Factors of Tinea Pedis Disease Among Adults Attending Tikrit Teaching Hospital/ Iraq
Infectious Disorders - Drug Targets Diet and Nutritional Interventions with the Special Role of Myo-Inositol in Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal
Current Pharmaceutical Design Hepatic Lipid Metabolism Disorder and Atherosclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Current Strategies to Overcome Resistance to ALK-Inhibitor Agents
Current Drug Metabolism